black man talking to a woman in computer screen


Seton Hall Law Professor Jake Elberg and Brown University Professor Erin Fuse Brown examine the legal and patient-safety risks of direct-to-consumer telehealth and propose safeguards to protect the physician-patient relationship in a UC Davis Law Review article.




GLP-1 medications have rapidly reshaped the weight-loss market, fueled by demand, aggressive advertising and easier access through telehealth. In 2026, 11% of U.S. adults reported using GLP-1 medications for weight loss, nearly four times the 3% reported in 2024, according to Gallup. Companies such as Hims & Hers have expanded access to FDA-approved drugs, including Wegovy and Ozempic, through online platforms and cash-pay options. 

For Elberg, the rapid expansion of the market raises a question that extends beyond GLP-1s: What happens when the commercial pathway to a prescription becomes intertwined with the medical decision to prescribe it? 

Elberg, who spent 12 years prosecuting corporate health care fraud and corruption at the U.S. Department of Justice, explores the issue in a recently published article with Erin C. Fuse Brown, “Direct-to-Prescription Telehealth and the Corporatization of Medicine.” Brown is a Professor of Health Services, Policy & Practice and the Director of the Health Policy & Law Lab at the Brown University School of Public Health. The article is scheduled for publication in UC Davis Law Review in November 2026. 

The concern, Elberg and Brown said, is a new model of direct-to-prescription telehealth that differs from traditional direct-to-consumer pharmaceutical advertising. “This is a new development because it doesn't say, ‘Talk to your doctor about using these drugs,’” Elberg said. “It says, ‘Go to this website, and we will provide you with a doctor.’” That distinction can change the nature of the doctor-patient encounter. “Everybody involved in that interaction knows the point is to end up with a prescription for this particular drug,” Elberg said. 

In a traditional medical relationship, a prescription is supposed to reflect an independent judgment about what is best for the patient. But when a physician works within a system that generates revenue when a prescription is written, Elberg and Brown argue, the financial incentive can become embedded in the relationship. 

The issue is particularly significant as consumers increasingly encounter GLP-1 medications through physicians, social media, influencers and direct-to-consumer advertising. Elberg said the concern is not simply that a physician might intentionally act improperly. Instead, financial incentives can become part of the business structure. “Everybody involved knows you better be writing these prescriptions or the company isn't going to work,” he said. 

Those concerns are compounded by the limitations of existing law. Elberg and Fuse Brown examine federal statutes, including the Anti-Kickback Statute and Stark Law, which are designed in part to prevent inappropriate financial incentives in health care. But many direct-to-prescription telehealth transactions involve patients paying out of pocket rather than government health programs. “Existing tools are really not sufficient to address the concerns about these relationships and this behavior,” Elberg said. 

The authors propose giving state medical boards a stronger role in regulating financially conflicted prescribing relationships. They also propose a federal statute that would address the problem directly. The goal is not to restrict telehealth, which Elberg and Brown see as an important tool for improving access and affordability. Rather, it is to distinguish patient-centered care from prescription-driven commerce. 

“Telehealth as a whole is a wonderful thing because there are real concerns about access and affordability,” Elberg said. But when telehealth becomes a mechanism for obtaining a particular product rather than receiving care, the risks change. “The concern is that folks who are looking to not do the right thing have the ability to put that on steroids through telehealth.” 

For Elberg, the stakes extend beyond the current GLP-1 boom. Without meaningful safeguards, direct-to-prescription medicine could “proliferate and become the new normal,” with companies and influencers increasingly marketing medications directly to patients and steering them toward providers with few prescribing barriers. “That’s going to really change how medicine works,” Elberg warned. The implications could extend well beyond weight-loss drugs. 

“There’s nothing that would stop a pharmaceutical company from saying, ‘I’m going to have an influencer convince patients that they need this cholesterol medication or whatever drug they need for the issue they’re dealing with.’” 

Elberg and Brown’s forthcoming article ultimately asks where the line should be drawn between expanding access to care and allowing commercial interests to shape medical judgment. As telehealth, pharmaceutical marketing and consumer demand increasingly converge, that line may help determine not only how patients access medicine, but how medicine itself is delivered. 

Professor Jake Elberg teaches Health Care Fraud & Corruption and serves as faculty director of Seton Hall Law’s Center for Health & Pharmaceutical Law and its global Health Care Compliance Certificate Programs around the world.

For more information, please contact:
Office of Communications and Marketing
(973) 642-8714
[email protected]